Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3283334 | Clinical Gastroenterology and Hepatology | 2011 | 6 Pages |
Abstract
Clostridium difficile infection is increasing in incidence, severity, and mortality. Treatment options are limited and appear to be losing efficacy. Recurrent disease is especially challenging; extended treatment with oral vancomycin is becoming increasingly common but is expensive. Fecal microbiota transplantation is safe, inexpensive, and effective; according to case and small series reports, about 90% of patients are cured. We discuss the rationale, methods, and use of fecal microbiota transplantation.
Keywords
IVIgFDAFMTHAVCDIIBSmTORDiarrheaenzyme immunoassayimmunoglobulin EIAIntravenous immunoglobulinGastrointestinalFood and Drug Administrationirritable bowel syndromeRecurrent infectionClostridium difficile infectionMicrobiotamammalian target of rapamycinpolymerase chain reactionPCRhuman immunodeficiency virusHIVHAV, Hepatitis A virusTransplantationfecal microbiota transplantationClostridium difficile
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Johan S. Bakken, Thomas Borody, Lawrence J. Brandt, Joel V. Brill, Daniel C. Demarco, Marc Alaric Franzos, Colleen Kelly, Alexander Khoruts, Thomas Louie, Lawrence P. Martinelli, Thomas A. Moore, George Russell, Christina Surawicz,